首頁 > 市場調查報告書 > 製藥

個人化醫學

市場調查報告書

商品編碼

1533615

精準醫療市場規模、佔有率和成長分析：按類型、適應症、最終用途和地區分類 - 產業預測，2024-2031 年

Precision Medicine Market Size, Share, Growth Analysis, By Type (Inhibitor Drugs, Monoclonal Antibodies), By Indication (Oncology, Infectious Diseases), By End-use (Hospitals and Clinics, Home Care Settings), By Region - Industry Forecast 2024-2031

出版日期: 2024年08月09日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球精準醫療市場規模將達285億美元，預測期間（2024-2031年）複合年成長率為11.4%，從2023年的317.5億美元成長到2031年的753億美元。

基因組研究、生物技術和資料分析的進步預計將推動精準醫療市場的顯著成長。癌症和心血管疾病等慢性疾病的盛行率不斷上升，推動了對精準醫療提供的個人化治療計劃的需求。這種方法是基於這樣的想法：即使是同一種疾病，也會根據遺傳和環境因素對治療產生不同的反應。根據SkyQuest分析，2023年全球精準醫療治療支出達380.9億美元。精準醫學會考慮患者的症狀、遺傳訊息和環境影響來調整治療策略。系統生物學和泛組學經常參與研究患者症狀的分子原因並開發標靶治療。精準醫療的好處包括根據個人需求和疾病類型量身定做更有效的治療方法，有可能降低治療成本並最大限度地減少不必要的藥物干預。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Illumina, Inc.（US）
Thermo Fisher Scientific Inc.（US）
Novartis AG（Switzerland）
Abbott Laboratories（US）
Agilent Technologies（US）
Almac Group（Northern Ireland）
Amgen Inc.（US）
Astellas Pharma Inc.（Japan）
AstraZeneca PLC（United Kingdom）
Bio-Rad Laboratories, Inc.（US）
Bristol-Myers Squibb Company（US）
Danaher Corporation（US）
F. Hoffmann-La Roche Ltd.（Switzerland）
GE Healthcare（US）
Intomics A/S（Denmark）
Merck & Co., Inc.（US）
Myriad Genetics, Inc.（US）
Pfizer Inc.（US）
Qiagen NV（Germany）
Quest Diagnostics（US）

簡介目錄

Product Code: SQMIG35B2061

Global Precision Medicine Market size was valued at USD 28.50 billion in 2022 and is poised to grow from USD 31.75 billion in 2023 to USD 75.30 billion by 2031, growing at a CAGR of 11.4% in the forecast period (2024-2031).

The precision medicine market is projected to experience significant growth, driven by advances in genomic research, biotechnology, and data analytics. The rising prevalence of chronic diseases, such as cancer and cardiovascular conditions, is fueling demand for personalized treatment plans that precision medicine provides. This approach is based on the concept that individuals with the same disease may respond differently to treatment based on their unique genetic and environmental factors. Based on SkyQuest's analysis, global spending on precision medicine treatments reached USD 38.09 billion in 2023. Precision medicine takes into account a patient's symptoms, genetic information, and environmental influences to tailor treatment strategies. It often involves system biology and pan-omics to investigate the molecular causes of a patient's condition and develop targeted therapies. The benefits of precision medicine include more effective treatments customized to individual needs and disease types, potentially reducing treatment costs and minimizing unnecessary pharmaceutical interventions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Precision Medicine Software market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Precision Medicine Software Market Segmental Analysis

The precision medicine market is segmented based on Type, Indication, End-user, and Region. Based on Type, the market is segmented into Inhibitor Drugs, Monoclonal Antibodies, Cell and Gene Therapy, Antiviral and Antiretroviral Drugs, and Others. Based on Indication, the market is segmented into Oncology, Rare Diseases, Infectious Diseases, Hematological Disorders, and Others. Based on End-user, the market is segmented into Hospitals & Clinics, and Home Care Settings. Based on Region, the market is segmented into North America, Europe, Asia-Pacific, South America, and Middle East and Africa.

Drivers of the Global Precision Medicine Software Market

Advancements in cancer biologics are a key driver behind the growth of precision medicine in the global market. The development of innovative therapeutic approaches, such as gene therapy for cancer treatment, is also expected to further accelerate market expansion. Precision medicine provides customized solutions tailored to patients' genetic profiles and disease characteristics, offering the potential for better outcomes and fewer side effects compared to traditional treatments.

Restraints in the Global Precision Medicine Software Market

Precision medicine is advancing rapidly, but the rising costs of diagnostics could hinder market growth. The process of diagnosing and treating patients generates a substantial amount of personal data, and associated privacy risks may restrict the market's expansion. Additionally, stringent regulations and standards are posing challenges to the growth of the personalized medicine sector.

Market Trends of the Global Precision Medicine Software Market

A key trend in the precision medicine market is the integration of advanced computer technologies, such as artificial intelligence (AI) and machine learning, into medication management. These technologies help organize extensive health and genetic data, leading to improved insights into disease patterns and treatment effectiveness. AI identifies new health indicators and develops personalized treatment strategies, enhancing research and care quality. This shift is driving innovative approaches and smart strategies in the adoption of precision medicine.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Supply Chain Analysis
Pipeline Analysis
Patent Analysis
Trade Analysis
Customer & Buying Criteria Analysis
Ecosystem of the Market
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Global Precision Medicine Market by Type

Market Overview
Inhibitor drugs
Monoclonal antibodies
Cell and gene therapy
Antiviral and antiretroviral drugs
Other therapeutic products

Global Precision Medicine Market by Indication

Market Overview
Oncology
Rare diseases
Infectious diseases
Hematological disorders
Other indications

Global Precision Medicine Market by End User

Market Overview
Hospitals and Clinics
Home Care Settings

Global Precision Medicine Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Illumina, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Almac Group (Northern Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE Healthcare (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Intomics A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Qiagen N.V. (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quest Diagnostics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments